Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20160085 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL23116158 | 0.75 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1772796 | 0.75 | TSHR (0.50) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1242674 | 0.75 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL612506 | 0.74 | KDM4E (1.00) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24616729 | 0.71 | ALDH1A1 (0.69) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1187755 | 0.71 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2763888 | 0.71 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6631672 | 0.70 | ALDH1A1 (0.69) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13746610 | 0.70 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| EP-3174881-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016618-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016618-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2016-02-04 | — | — | WO | disclosed |
| CN-102007127-A | Furo- and thieno [3,2-c] pyridines | OSI PHARM INC | 2011-04-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | KDM4E 2816/4885ALDH1A1 508/4885SMN1; SMN2 837/4885 |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | KDM4E 2816/4885ALDH1A1 508/4885SMN1; SMN2 837/4885 |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, BCL2 | KDM4E 2771/4885ALDH1A1 632/4885SMN1; SMN2 705/4885 |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNI, CCNB1 | KDM4E 2985/4885ALDH1A1 499/4885SMN1; SMN2 854/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | KDM4E 2816/4885ALDH1A1 508/4885SMN1; SMN2 837/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | KDM4E 2816/4885ALDH1A1 508/4885SMN1; SMN2 837/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | KDM4E 2816/4885ALDH1A1 508/4885SMN1; SMN2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.